Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, Jin Q, Su L, Liu X, Wang K, Yan G, Dong T, Wu S, Zhou P, Zhang J, Liang W, Ren J, Teng Y, Chen C, Xu XH. Mol Ther. 2019 Jun 5;27(6):1114-1125. ...
Treatment of Intervertebral Disk Disease by the Administration of mRNA Encoding a Cartilage-Anabolic Transcription Factor
Lin CY, Crowley ST, Uchida S, Komaki Y, Kataoka K, Itaka K. Mol Ther Nucleic Acids. 2019 Jun 7;16:162-171. PubMed
The roles of structural dynamics in the cellular functions of RNAs
Ganser LR, Kelly ML, Herschlag D, Al-Hashimi HM. Nat Rev Mol Cell Biol. 2019 Jun 10. PubMed
Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides
Wang Y, Yu RZ, Henry S, Geary RS. Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):475-485. PubMed
Targeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM. ...
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA 3rd, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Murray SF, Greenlee S, Crooke RM, Liang XH, Seth PP, Crooke ST. Nat Biotechnol. 2019 Apr 29. PubMed
Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations
Huang L, Aghajan M, Quesenberry T, Low A, Murray SF, Monia BP, Guo S. Nucleic Acid Ther. 2019 May 9. PubMed
Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates
Ă˜stergaard ME, Jackson M, Low A, E Chappell A, G Lee R, Peralta RQ, Yu J, Kinberger GA, Dan A, Carty R, Tanowitz M, Anderson P, Kim TW, Fradkin L, Mullick AE, Murray S, Rigo F, Prakash TP, Bennett CF, Swayze EE, Gaus HJ, Seth ...
ApoC-III ASO Promotes Tissue LPL Activity in Absence of ApoE-Mediated TRL Clearance
Ramms B, Patel S, Nora C, Pessentheiner AR, Chang MW, Green CR, Golden GJ, Secrest P, Krauss RM, Metallo CM, Benner C, Alexander VJ, Witztum JL, Tsimikas S, Esko JD, Gordts PLSM. J Lipid Res. 2019 May 14. PubMed
Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease
Uehara T, Choong CJ, Nakamori M, Hayakawa H, Nishiyama K, Kasahara Y, Baba K, Nagata T, Yokota T, Tsuda H, Obika S, Mochizuki H. Sci Rep. 2019 May 21;9(1):7567. PubMed
